Yale Cancer Center | Strategic Alliance Partners

November 02, 2016

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

October 26, 2016

Erin Wysong Hofstatter, MD, associate professor, co-director, Cancer Genetics and Prevention Program, Yale Cancer Center, discusses what impact the advancements with molecular testing have had on the identification of genetic abnormalities in patients with breast cancer.

October 26, 2016

Marcus Bosenberg, MD, PhD, associate professor of dermatology and pathology, Yale University, discusses mouse models for testing immunotherapies.

October 11, 2016

PARP inhibitors still have a place in the treatment paradigm of triple-negative breast cancer, but the role of these agents are significantly evolving.

October 06, 2016

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer with brain metastases to determine the best option for treatment.

October 06, 2016

Pooled data from ten universities finds added benefit from radiation boost among patients with negative margins following breast-conserving surgery.

October 05, 2016

In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival.

October 05, 2016

The association between provider case volume and outcomes has long been suggested in cancer care.

September 23, 2016

Brigid Killelea, MD, MPH, FACS, associate professor of surgery (oncology), Yale Cancer Center, discusses the potential of nipple-sparing mastectomy for women who undergo surgery for breast cancer.

September 23, 2016

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, explains some of the most discussed topics in breast cancer. Chagpar was recently the chair at the State of the Science Summit on Breast Cancer held Sept. 15.

September 21, 2016

Barbara A. Burtness, MD, discussed the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.

September 21, 2016

Malini Harigopal, MD, associate professor of Pathology, interim director of Breast Pathology, Yale School of Medicine, Yale Cancer Center, discusses the advancements in the pathology of breast cancer.

September 21, 2016

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.

September 20, 2016

Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved.

July 26, 2016

Daniel P. Petrylak, MD, professor of Medicine, Yale Cancer Center, discusses his vision for radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and how it integrates with chemotherapy and other agents for treatment of this patient population.

March 30, 2016

Vincent T. DeVita Jr, MD, discusses his insights into the operations of the FDA and the National Cancer Institute will hold a special appeal for oncology specialists and healthcare providers in his book, "The Death of Cancer."

March 22, 2016

Mario Sznol, MD, discusses the current state of immunotherapy in renal cell carcinoma, emerging agents and combinations in the field, and the challenges that arise with finding biomarkers.

March 01, 2016

Madhav Dhodapkar, MBBS, discusses research showing that nflammation and chronic stimulation of the immune system by lipids may trigger multiple myeloma in approximately one-third of all cases.

February 26, 2016

Yale Cancer Center researchers have identified a link between lipids and a third of all myelomas, a type of cancer affecting plasma cells.

February 26, 2016

A team of researchers from Yale School of Public Health and Yale Cancer Center recently published a study in the Journal of Cancer Survivorship that addresses the needs of cancer survivors who are at least nine years beyond an initial diagnosis.